NCT06264388招募中2 期
A Biomarker-Guided Phase 2 Study of DB107-RRV (Retroviral Replicating Vector) Combined With DB107-Flucytosine Extended-Release Tablets in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- Ashish Shah
- 入组人数
- 33
- 试验地点
- 2
- 主要终点
- Progression Free Survival
研究概览
简要总结
The purpose of this study is to determine if the investigational products, DB107-RRV and DB107-FC, as a combination treatment will shrink high-grade glioma (HGG) in patients with recurrent/progressive, resectable or unresectable disease and increase the time that disease is controlled.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients 18-75 years old.
- •Histologically proven HGG that have recurred/progressed (first or second recurrence).
- •Patients with unresectable or resectable HGG (AA or GBM) will be enrolled.
- •Measurable disease on MRI as evidenced by 1 cm on two separate dimensions on MRI fluid attenuated inversion recovery (FLAIR) (non-enhancing) or contrast-enhancement.
- •Last temozolomide dosage 4 weeks prior to surgery.
- •Patients with prior radiation therapy are allowed, but histological tumor diagnosis of recurrent tumor must be confirmed according to the RANO criteria. Recurrence must be confirmed by diagnostic biopsy with local pathology review or contrast-enhanced MRI. If first recurrence of GBM is documented by MRI, an interval of at least 12 weeks after the end of prior radiation therapy is required unless there is either: i) histopathologic confirmation of recurrent tumor, or ii) new enhancement on MRI outside of the radiotherapy treatment field.
- •Presence of Denovo Genomic Marker 7 (DGM7) biomarker in blood.
- •Laboratory values (Platelet count ≥ 80,000, hemoglobin [Hg] ≥10 g/dL, absolute neutrophil count (ANC) > 1,500 cells/mm3, absolute lymphocyte count (ALC) > 500/mm3) and adequate liver function, total bilirubin< 1.5 upper limit of normal (ULN), alanine transaminase (ALT) <2.5 ULN. Estimated glomerular filtration rate (eGFR) should be > 50 mL/min (Cockcroft Gault Formula). Patients with aspartate transaminase (AST) or ALT values >3 ULN and total bilirubin >1.5 mg/dL will be excluded.
- •Patients cannot be pregnant at the time of enrollment or during the study. Patients willing to use one (1) effective method of contraception in addition to barrier methods (condoms) from the time of signing the informed consent form until 12 months after receiving the last dose of DB107-RRV or until there is no evidence of DB107-RRV in their blood, whichever is longer.
- •Karnofsky Performance Score (KPS) ≥
- •Patient is able to consent and abide by protocol.
排除标准
- •History of active other malignancy (other than non-melanoma skin cancers, cervical ductal carcinoma in situ or localized prostate cancer) within 5 years.
- •Multifocal gliomas that cannot undergo stereotactic biopsy/administration of DB107-RRV will be excluded. Patients with 3 or more intracranial recurrences will be excluded.
- •Histologically confirmed oligodendroglioma or mixed gliomas.
- •History of human immunodeficiency virus (HIV) infection or other forms of severe immunosuppression.
- •Patients with impaired renal function (eGFR<50 cc/min).
- •Patients with bone marrow depression, such as those with a hematological disease or who are being treated with radiation or drugs that depress bone marrow or individuals who have a history of treatment with drugs or radiation that depress bone marrow within 1 month of enrollment.
- •The patient intends to undergo treatment with the Gliadel® wafer at the time of this surgery or has received the Gliadel® wafer < 30 days from surgery.
- •Allergy to 5-FC.
- •Gastrointestinal diseases that prevent absorption of medications such as 5-FC.
- •Pregnancy or patients who are actively breast-feeding.
- •Recent use of cytosine arabinoside (< 3 weeks).
- •Recent treatment with bevacizumamab (< 3 weeks).
- •Recent treatment with temozolomide (<4 weeks).
- •History of bleeding diathesis or current anti-coagulant or anti-platelet usage, including nonsteroidal anti-inflammatory drugs (NSAIDs), at the time of the scheduled resection that cannot be stopped for surgery.
- •Sustained dependence on systemic dexamethasone (>8 mg/day) one month prior to surgery.
- •Severe systemic illnesses including cardiopulmonary dysfunction (New York Heart Association > Grade 2 congestive heart failure (CHF), uncontrolled arrhythmias, significant pulmonary disease > Grade 2 dyspnea) or other serious medical condition or social situations that in the judgement of the Investigator(s) would interfere or limit compliance with study requirements/treatments.
- •The patient has or had any active infection requiring systemic antibiotic, antifungal or antiviral therapy within the past 4 weeks.
- •Current or active coronavirus disease (COVID-19) disease, positive quantitative polymerase chain reaction (qPCR) result.
- •Patients with impaired decision-making capacity.
- •Patients who are currently receiving investigational medications or medical device(s) within 4 weeks (or 5 half-lives of the investigational medication(s), whichever is shorter) prior to enrollment.
- •Patients who have any other disease, either metabolic or psychological, which as per Investigator assessment may affect the patient's compliance or place the patient at higher risk of potential treatment complications.
研究组 & 干预措施
DB107-RRV and DB107-FC Group
Experimental
Patients will receive DB107-RRV during the tumor resection/biopsy procedure. Approximately 6 weeks after surgery, patients will start drug therapy with a 7-day oral regimen of 220 mg/kg/day DB107-FC, which is to be self-administered. This 7-day regimen, which is considered one cycle of treatment, is to be repeated every 6 weeks for up to 12 months. Patients will undergo follow up procedures for at least 5 years after last DB107-RRV treatment.
干预措施: DB107-FC (Drug)
DB107-RRV and DB107-FC Group
Experimental
Patients will receive DB107-RRV during the tumor resection/biopsy procedure. Approximately 6 weeks after surgery, patients will start drug therapy with a 7-day oral regimen of 220 mg/kg/day DB107-FC, which is to be self-administered. This 7-day regimen, which is considered one cycle of treatment, is to be repeated every 6 weeks for up to 12 months. Patients will undergo follow up procedures for at least 5 years after last DB107-RRV treatment.
干预措施: DB107-RRV (Drug)
结局指标
主要结局
Progression Free Survival
时间窗: Up to 24 Months
Progression free survival (PFS) is defined as duration from initiation of treatment to the point of disease progression or death.
Overall Survival
时间窗: Up to 24 Months
Overall survival (OS) refers to the duration from the initiation of enrollment until death, regardless of the cause.
次要结局
- Number of Treatment Related Toxicities(Up to 5 Years)
- Durable Clinical Benefit Rate (DCBR)(Up to 5 Years)
- Duration of Durable Response Rate(12 Months)
- Assessment of Tumor Status Measured by Response Assessment in Neuro-oncology (RANO) Criteria(Up to 5 Years)
- Durable Response Rate (DRR)(Up to 5 Years)
研究者
Ashish Shah
Assistant Professor of Clinical
University of Miami
研究点 (2)
Loading locations...
相似试验
招募中
1 期
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade GliomaHigh Grade GliomaMGMT-Unmethylated GlioblastomaMGMT-Methylated GlioblastomaNCT06504381University of California, San Francisco70
已完成
3 期
A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary HypercholesterolemiaEssential HypertensionPrimary HypercholesterolemiaNCT05930028Boryung Pharmaceutical Co., Ltd148
招募中
1 期
A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal TumorsHer2-positive/Low-expression Urinary and Digestive Tract TumorsNCT06031584Sichuan Baili Pharmaceutical Co., Ltd.42
已完成
2 期
Study of rBet v1 TabletsBirch Pollen-related RhinoconjunctivitisRhinitis, Allergic, SeasonalNCT00901914Stallergenes Greer483
已完成
1 期
A Study to Evaluate Drug-drug Interactions Between BR1017-1 and BR1017-2 in Healthy VolunteersHypercholesterinemiaHypertensionNCT05372380Boryung Pharmaceutical Co., Ltd32